Filing Flows › Heron Therapeutics (HRTX) › Guidance history
Heron Therapeutics (HRTX) guidance history: what it guided and what it reported
Heron Therapeutics gave guidance in 3 earnings releases on file since May 11, 2026.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $173M–$183M (May 11, 2026) | — | to be reported | — |
Adjusted revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $173M–$183M (May 11, 2026) | — | to be reported | — |
Free cash flow
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2027 | $45.0M–$60.0M (Nov 9, 2026) | — | to be reported | — |
| FY2026 | $45.0M–$60.0M (Nov 9, 2026) | — | to be reported | — |
Adjusted EBITDA
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $10.0M–$20.0M (May 11, 2026) | — | to be reported | — |
The latest quarter
Heron Therapeutics, Q3 2026: revenue $35.2M (-8% year over year), operating margin -4.7%, net loss $5.0M, operating cash flow −$794K. The chart follows the revenue to costs, profit and cash.
Questions
Does Heron Therapeutics beat its guidance?
Heron Therapeutics gave guidance in 3 earnings releases on file since May 11, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.